Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis
Chun-Hong Xie, Min Wei, Fei-Yan Yang, Fu-Zhen Wu, Lei Chen, Jian-Kun Wang, Qin Liu, Jin-Xiong Huang Department of Hematology, Affiliated Liuzhou People’s Hospital of Guangxi University of Science and Technology (Liuzhou People’s Hospital), Liuzhou 545000, Guangxi, China Backgroun...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-09-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/efficacy-and-safety-of-lenalidomide-for-the-treatment-of-acute-myeloid-peer-reviewed-article-CMAR |
| _version_ | 1819095119452700672 |
|---|---|
| author | Xie CH Wei M Yang FY Wu FZ Chen L Wang JK Liu Q Huang JX |
| author_facet | Xie CH Wei M Yang FY Wu FZ Chen L Wang JK Liu Q Huang JX |
| author_sort | Xie CH |
| collection | DOAJ |
| description | Chun-Hong Xie, Min Wei, Fei-Yan Yang, Fu-Zhen Wu, Lei Chen, Jian-Kun Wang, Qin Liu, Jin-Xiong Huang Department of Hematology, Affiliated Liuzhou People’s Hospital of Guangxi University of Science and Technology (Liuzhou People’s Hospital), Liuzhou 545000, Guangxi, China Background: Lenalidomide is effective for the treatment of low-risk myelodysplastic syndromes with deletion 5q abnormalities. However, whether lenalidomide leads to a significant improvement in treatment response and overall survival (OS) in cases of acute myeloid leukemia (AML) remains controversial. A systematic review and a meta-analysis were performed to evaluate the efficacy and safety of lenalidomide in the treatment of AML.Methods: Clinical studies were identified from the Cochrane Central Register of Controlled Trials, PubMed, Embase, and ClinicalTrials.gov. Efficacy outcomes included overall response rate (ORR), complete remission (CR), and OS. Safety was evaluated based on the incidence of grade 3 and 4 treatment-related adverse events (AEs).Results: Eleven studies were included in our meta-analysis; collectively these studies featured 407 AML patients. Pooled estimates for overall ORR and CR were 31% (95% CI: 26%–36%) and 21% (95% CI: 16%–27%), respectively. Thrombocytopenia, anemia, neutropenia, and infection were the most common grade 3 and 4 AEs.Conclusion: Lenalidomide may have some clinical activity in AML, but the population that would benefit from lenalidomide and incorporating lenalidomide into combination drug strategies need to be better defined. Keywords: azacitidine, cytarabine, immunomodulatory agent, cytogenetic risk |
| first_indexed | 2024-12-21T23:38:14Z |
| format | Article |
| id | doaj.art-6d1a9a7ab59d4c35be519af97a511086 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-21T23:38:14Z |
| publishDate | 2018-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-6d1a9a7ab59d4c35be519af97a5110862022-12-21T18:46:17ZengDove Medical PressCancer Management and Research1179-13222018-09-01Volume 103637364840690Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysisXie CHWei MYang FYWu FZChen LWang JKLiu QHuang JXChun-Hong Xie, Min Wei, Fei-Yan Yang, Fu-Zhen Wu, Lei Chen, Jian-Kun Wang, Qin Liu, Jin-Xiong Huang Department of Hematology, Affiliated Liuzhou People’s Hospital of Guangxi University of Science and Technology (Liuzhou People’s Hospital), Liuzhou 545000, Guangxi, China Background: Lenalidomide is effective for the treatment of low-risk myelodysplastic syndromes with deletion 5q abnormalities. However, whether lenalidomide leads to a significant improvement in treatment response and overall survival (OS) in cases of acute myeloid leukemia (AML) remains controversial. A systematic review and a meta-analysis were performed to evaluate the efficacy and safety of lenalidomide in the treatment of AML.Methods: Clinical studies were identified from the Cochrane Central Register of Controlled Trials, PubMed, Embase, and ClinicalTrials.gov. Efficacy outcomes included overall response rate (ORR), complete remission (CR), and OS. Safety was evaluated based on the incidence of grade 3 and 4 treatment-related adverse events (AEs).Results: Eleven studies were included in our meta-analysis; collectively these studies featured 407 AML patients. Pooled estimates for overall ORR and CR were 31% (95% CI: 26%–36%) and 21% (95% CI: 16%–27%), respectively. Thrombocytopenia, anemia, neutropenia, and infection were the most common grade 3 and 4 AEs.Conclusion: Lenalidomide may have some clinical activity in AML, but the population that would benefit from lenalidomide and incorporating lenalidomide into combination drug strategies need to be better defined. Keywords: azacitidine, cytarabine, immunomodulatory agent, cytogenetic riskhttps://www.dovepress.com/efficacy-and-safety-of-lenalidomide-for-the-treatment-of-acute-myeloid-peer-reviewed-article-CMARazacitidineoverall response ratecomplete remissionadverse events. |
| spellingShingle | Xie CH Wei M Yang FY Wu FZ Chen L Wang JK Liu Q Huang JX Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis Cancer Management and Research azacitidine overall response rate complete remission adverse events. |
| title | Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis |
| title_full | Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis |
| title_fullStr | Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis |
| title_short | Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis |
| title_sort | efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia a systematic review and meta analysis |
| topic | azacitidine overall response rate complete remission adverse events. |
| url | https://www.dovepress.com/efficacy-and-safety-of-lenalidomide-for-the-treatment-of-acute-myeloid-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT xiech efficacyandsafetyoflenalidomideforthetreatmentofacutemyeloidleukemiaasystematicreviewandmetaanalysis AT weim efficacyandsafetyoflenalidomideforthetreatmentofacutemyeloidleukemiaasystematicreviewandmetaanalysis AT yangfy efficacyandsafetyoflenalidomideforthetreatmentofacutemyeloidleukemiaasystematicreviewandmetaanalysis AT wufz efficacyandsafetyoflenalidomideforthetreatmentofacutemyeloidleukemiaasystematicreviewandmetaanalysis AT chenl efficacyandsafetyoflenalidomideforthetreatmentofacutemyeloidleukemiaasystematicreviewandmetaanalysis AT wangjk efficacyandsafetyoflenalidomideforthetreatmentofacutemyeloidleukemiaasystematicreviewandmetaanalysis AT liuq efficacyandsafetyoflenalidomideforthetreatmentofacutemyeloidleukemiaasystematicreviewandmetaanalysis AT huangjx efficacyandsafetyoflenalidomideforthetreatmentofacutemyeloidleukemiaasystematicreviewandmetaanalysis |